Skip to main content
Top
Published in: Neurocritical Care 1/2011

01-08-2011 | Original Article

Levetiracetam is Associated with Improved Cognitive Outcome for Patients with Intracranial Hemorrhage

Authors: Scott Taylor, Robin J. Heinrichs, Jeff M. Janzen, As’ad Ehtisham

Published in: Neurocritical Care | Issue 1/2011

Login to get access

Abstract

Background

To date, common therapy in patients with intracranial hemorrhage (ICH) includes prophylaxis of seizure using antiepileptic drugs, commonly phenytoin. Phenytoin therapy is associated with a high incidence of cognitive disturbance. Levetiracetam is known to cause less cognitive disruption and may be a suitable alternative for seizure prophylaxis. Cognitive outcomes in ICH patients receiving seizure prophylaxis with levetiracetam or phenytoin are compared.

Method

A retrospective chart review was conducted with 269 patients who received prophylactic levetiracetam or phenytoin between August 2005 and May 2008. A total of 85 reviewed patients met inclusion criteria (phenytoin n = 25, levetiracetam n = 60).

Results

Statistically significant results included higher Glasgow Coma Scores (GCS) at dismissal (median, 14 vs. 11, P = 0.023), lower seizure incidence (0.0 vs. 8%, P = 0.03) for patients receiving levetiracetam than those treated with phenytoin and patients being discharged home (21.7% vs. 16%, P = 0.03). Observed trends included greater cognitive function retention rate (56.7% vs. 36%, P = 0.08).

Conclusion

Despite similarities in hemorrhage type and severity at onset, patients receiving levetiracetam had better cognition at discharge and fewer seizures than patients receiving phenytoin. These data suggest that levetiracetam is more effective than phenytoin for seizure prophylaxis without suppression of cognitive abilities in patients with ICH.
Literature
1.
go back to reference Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics–2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119(3):e21–181.PubMedCrossRef Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics–2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119(3):e21–181.PubMedCrossRef
2.
go back to reference Hart R, Byer J, Slaughter J, Hewett J, Easton J. Occurrence and implications of seizures in subarachnoid hemorrhage due to ruptured intracranial aneurysms. Neurosurgery. 1981;8(4):417–21.PubMedCrossRef Hart R, Byer J, Slaughter J, Hewett J, Easton J. Occurrence and implications of seizures in subarachnoid hemorrhage due to ruptured intracranial aneurysms. Neurosurgery. 1981;8(4):417–21.PubMedCrossRef
3.
go back to reference Keränen T, Tapaninaho A, Hernesniemi J, Vapalahti M. Late epilepsy after aneurysm operations. Neurosurgery. 1985;17(6):897–900.PubMedCrossRef Keränen T, Tapaninaho A, Hernesniemi J, Vapalahti M. Late epilepsy after aneurysm operations. Neurosurgery. 1985;17(6):897–900.PubMedCrossRef
5.
go back to reference Olafsson E, Gudmundsson G, Hauser W. Risk of epilepsy in long-term survivors of surgery for aneurysmal subarachnoid hemorrhage: a population-based study in Iceland. Epilepsia. 2000;41(9):1201–5.PubMedCrossRef Olafsson E, Gudmundsson G, Hauser W. Risk of epilepsy in long-term survivors of surgery for aneurysmal subarachnoid hemorrhage: a population-based study in Iceland. Epilepsia. 2000;41(9):1201–5.PubMedCrossRef
6.
go back to reference Ryvlin P, Montavont A, Nighoghossian N. Optimizing therapy of seizures in stroke patients. Neurology. 2006;67(12 Suppl 4):S3–9.PubMed Ryvlin P, Montavont A, Nighoghossian N. Optimizing therapy of seizures in stroke patients. Neurology. 2006;67(12 Suppl 4):S3–9.PubMed
7.
go back to reference Chumnanvej S, Dunn I, Kim D. Three-day phenytoin prophylaxis is adequate after subarachnoid hemorrhage. Neurosurgery. 2007;60(1):99–102. (discussion 102–103).PubMedCrossRef Chumnanvej S, Dunn I, Kim D. Three-day phenytoin prophylaxis is adequate after subarachnoid hemorrhage. Neurosurgery. 2007;60(1):99–102. (discussion 102–103).PubMedCrossRef
8.
go back to reference Choudhari K, Kaliaperumal C. Three-day phenytoin prophylaxis is adequate after subarachnoid hemorrhage. Neurosurgery. 2007;61(6):E1340. (author reply E1340).PubMedCrossRef Choudhari K, Kaliaperumal C. Three-day phenytoin prophylaxis is adequate after subarachnoid hemorrhage. Neurosurgery. 2007;61(6):E1340. (author reply E1340).PubMedCrossRef
9.
go back to reference Zubkov A, Wijdicks E. Antiepileptic drugs in aneurysmal subarachnoid hemorrhage. Rev Neurol Dis. 2008;5(4):178–81.PubMed Zubkov A, Wijdicks E. Antiepileptic drugs in aneurysmal subarachnoid hemorrhage. Rev Neurol Dis. 2008;5(4):178–81.PubMed
10.
go back to reference Carpay J, Aldenkamp A, van Donselaar C. Complaints associated with the use of antiepileptic drugs: results from a community-based study. Seizure. 2005;14(3):198–206.PubMedCrossRef Carpay J, Aldenkamp A, van Donselaar C. Complaints associated with the use of antiepileptic drugs: results from a community-based study. Seizure. 2005;14(3):198–206.PubMedCrossRef
11.
go back to reference Naidech A, Kreiter K, Janjua N, et al. Phenytoin exposure is associated with functional and cognitive disability after subarachnoid hemorrhage. Stroke. 2005;36(3):583–7.PubMedCrossRef Naidech A, Kreiter K, Janjua N, et al. Phenytoin exposure is associated with functional and cognitive disability after subarachnoid hemorrhage. Stroke. 2005;36(3):583–7.PubMedCrossRef
12.
go back to reference Díaz R, Sancho J, Serratosa J. Antiepileptic drug interactions. Neurologist. 2008;14(6 Suppl 1):S55–65.PubMedCrossRef Díaz R, Sancho J, Serratosa J. Antiepileptic drug interactions. Neurologist. 2008;14(6 Suppl 1):S55–65.PubMedCrossRef
13.
go back to reference Rogawski M. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res. 2006;69(3):273–94.PubMedCrossRef Rogawski M. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res. 2006;69(3):273–94.PubMedCrossRef
14.
go back to reference Arif H, Buchsbaum R, Weintraub D, Pierro J, Resor SJ, Hirsch L. Patient-reported cognitive side effects of antiepileptic drugs: predictors and comparison of all commonly used antiepileptic drugs. Epilepsy Behav. 2009;14(1):202–9.PubMedCrossRef Arif H, Buchsbaum R, Weintraub D, Pierro J, Resor SJ, Hirsch L. Patient-reported cognitive side effects of antiepileptic drugs: predictors and comparison of all commonly used antiepileptic drugs. Epilepsy Behav. 2009;14(1):202–9.PubMedCrossRef
15.
go back to reference Nau K, Divertie G, Valentino A, Freeman W. Safety and efficacy of levetiracetam for critically ill patients with seizures. Neurocrit Care. 2009;11(1):34–7.PubMedCrossRef Nau K, Divertie G, Valentino A, Freeman W. Safety and efficacy of levetiracetam for critically ill patients with seizures. Neurocrit Care. 2009;11(1):34–7.PubMedCrossRef
16.
go back to reference Szaflarski J, Meckler J, Szaflarski M, Shutter L, Privitera M, Yates S. Levetiracetam use in critically ill patients. Neurocrit Care. 2007;7(2):140–7.PubMedCrossRef Szaflarski J, Meckler J, Szaflarski M, Shutter L, Privitera M, Yates S. Levetiracetam use in critically ill patients. Neurocrit Care. 2007;7(2):140–7.PubMedCrossRef
17.
go back to reference Lynch B, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA. 2004;101(26):9861–6.PubMedCrossRef Lynch B, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA. 2004;101(26):9861–6.PubMedCrossRef
Metadata
Title
Levetiracetam is Associated with Improved Cognitive Outcome for Patients with Intracranial Hemorrhage
Authors
Scott Taylor
Robin J. Heinrichs
Jeff M. Janzen
As’ad Ehtisham
Publication date
01-08-2011
Publisher
Humana Press Inc
Published in
Neurocritical Care / Issue 1/2011
Print ISSN: 1541-6933
Electronic ISSN: 1556-0961
DOI
https://doi.org/10.1007/s12028-010-9341-6

Other articles of this Issue 1/2011

Neurocritical Care 1/2011 Go to the issue